Can-Fite BioPharma logo
Can-Fite BioPharma
CANF | AMEX
Chart Builder DCF Calculator
$1.56
+$0.14 (+9.86%)
At close: Nov 16, 2026, 4:00 PM ET
$1.56
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:00 PM ET

Can-Fite BioPharma Company Profile

Company profile explained

Company Profile

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.

Key Executives

Name Position
Motti Farbstein Chief Executive Officer and Chief Financial & Operating Officer
Pnina Fishman Founder, Chief Scientific Officer & Executive Chairperson
Sari Fishman Vice President of Business Development
Stephen A. Harrison FACP Member of Clinical Advisory Board & Consulting Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 26, 2026 6-K Filing
Oct 09, 2026 EFFECT Filing
Oct 09, 2026 EFFECT Filing
Oct 09, 2026 424B3 Filing
Sep 25, 2026 F-3 Filing
Sep 25, 2026 F-3/A [Amend] Filing
Sep 11, 2026 EFFECT Filing
Sep 11, 2026 EFFECT Filing
Sep 10, 2026 D Filing
Sep 09, 2026 6-K Filing
View All SEC Filings ➞
Can-Fite BioPharma
Can-Fite BioPharma logo
Country Israel
IPO Date Nov 6, 2012
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Motti Farbstein

Contact Details

26 Ben Gurion Street Ramat Gan 5257346 Israel

Stock Details

Ticker Symbol CANF
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001536196
CUSIP Number 13471N409
ISIN Number US13471N4097
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.